20.1
肺高血圧症：分類と病因
肺高血圧症（PH）は、身体が安静な状態でも肺動脈圧の平均値が 25 mmHg 以上に上昇する重篤な健康状態です。心臓から肺に血液を運ぶ血管のこの高圧は、息切れなどのさまざまな症状を引き起こし、右心不全につながる可能性があり、全体的な生活の質に重大な影響を及ぼします。
PHにはさまざまな分類があり、そ…
肺高血圧症(PH)は、安静時平均肺動脈圧が25mmHg以上であることを示します。
肺高血圧症は、左心疾患、肺疾患または低酸素症によるPH、慢性血栓塞栓性PH、多因子メカニズムが不明なPH、および肺動脈性肺高血圧症またはPAHに分類できます。
PAHは、小さな動脈や細動脈の血管変化を特徴とするまれで致命的な状態であり、肺動脈圧と血管抵抗の上昇につながります。
PAHの主要なメカニズムには、肺血管のリモデリング、持続的な肺血管収縮、in situ血栓症、および肺血管壁の硬化が含まれます。
プロスタサイクリンのような血管作用性メディエーターの減少とET-1のような血管収縮薬の増加は、血管収縮の一因となります。
PHの症状には、呼吸困難、倦怠感、胸痛、失神などがあります。
PHの潜在的な治療選択肢には、cGMPシグナル伝達刺激剤、一酸化窒素療法、膜受容体拮抗薬およびアゴニスト、イオンチャネル遮断薬などがあります。
View the full transcript and gain access to JoVE Core videos
Q1: What is the diagnostic threshold for pulmonary hypertension?
Pulmonary hypertension is diagnosed when the resting mean pulmonary arterial pressure reaches 25 mm Hg or higher. This elevated pressure in the blood vessels transporting blood from the heart to the lungs can cause significant symptoms and lead to right heart failure. The condition affects overall quality of life and requires prompt medical evaluation.
Q2: How is pulmonary arterial hypertension different from other types of pulmonary hypertension?
Pulmonary arterial hypertension (PAH) is a rare, fatal form characterized by vascular changes in small arteries and arterioles, causing elevated pulmonary arterial pressure and vascular resistance. Unlike other PH types linked to left heart disease, lung disease, or blood clots, PAH involves distinct mechanisms including pulmonary vascular remodeling, sustained vasoconstriction, in situ thrombosis, and vascular wall stiffening.
Q3: What causes pulmonary vasoconstriction in pulmonary arterial hypertension?
Pulmonary vasoconstriction in PAH results from imbalanced vasoactive mediators. Decreased vasodilators like nitric oxide and prostacyclin reduce vessel widening, while increased vasoconstrictors like endothelin-1 (ET-1) promote narrowing and smooth muscle cell proliferation. This mediator imbalance drives sustained constriction and worsens vascular resistance.
Q4: What are the main symptoms of pulmonary hypertension?
Pulmonary hypertension symptoms include dyspnea (shortness of breath), fatigue, chest pain, and syncope (fainting). These symptoms typically worsen over time, progressively limiting patients' ability to perform routine activities. Early recognition of these signs is important for timely diagnosis and intervention.
Q5: What therapeutic mechanisms are used to treat pulmonary arterial hypertension?
Treatment for pulmonary arterial hypertension employs multiple mechanisms: cGMP signaling stimulators enhance vasodilation, nitric oxide therapies promote vessel widening, membrane receptor antagonists and agonists modulate vasoactive pathways, and ion channel blockers reduce vascular resistance. Treatment choice depends on PAH severity and patient health status.
Q6: How do the five classifications of pulmonary hypertension differ?
The five PH classifications are: PH due to left heart disease, PH from lung diseases or hypoxia, chronic thromboembolic PH (caused by blood clots), PH with unclear multifactorial mechanisms, and pulmonary arterial hypertension (PAH). Each classification relates to different underlying causes, treatment approaches, and prognoses, guiding clinical management decisions.
Q7: What structural changes occur in the pulmonary vasculature during pulmonary arterial hypertension?
PAH involves multiple vascular structural changes: pulmonary vascular remodeling alters vessel architecture, sustained vasoconstriction narrows blood vessels, in situ thrombosis causes clotting within vessels, and vascular wall stiffening reduces elasticity. These combined changes increase pulmonary arterial pressure and vascular resistance, progressively impairing lung blood flow.